12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Phase II data

Top-line data from the double-blind, placebo-controlled, international Phase II BCT-001 trial in 111 patients showed that twice-daily 30 mg oral apremilast met the primary endpoint of reducing the number of oral ulcers from baseline to week 12 vs. placebo....

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >